Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $11.00.

EVAX has been the topic of a number of recent research reports. Maxim Group assumed coverage on shares of Evaxion A/S in a research note on Thursday, February 19th. They set a “buy” rating and a $10.00 price target on the stock. Wall Street Zen downgraded shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. JonesTrading started coverage on shares of Evaxion A/S in a report on Tuesday, March 10th. They set a “buy” rating and a $10.00 target price on the stock. Lake Street Capital decreased their price target on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research note on Friday, January 9th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of EVAX. SmartHarvest Portfolios LLC purchased a new stake in Evaxion A/S during the 4th quarter worth about $72,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Evaxion A/S in the 4th quarter valued at about $38,000. Finally, Wesbanco Bank Inc. purchased a new position in shares of Evaxion A/S in the 4th quarter valued at about $48,000. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

Evaxion A/S Price Performance

EVAX opened at $3.77 on Tuesday. The stock’s 50-day moving average price is $3.54 and its 200 day moving average price is $4.72. Evaxion A/S has a 12-month low of $1.20 and a 12-month high of $12.15. The firm has a market cap of $31.44 million, a price-to-earnings ratio of -2.86 and a beta of 0.28. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.